The heart never takes a break. The heart is a strong muscle that never stops exercising, not even for a minute. Every minute, it needs blood, nourishment, and oxygen. At Amarillo Heart Institute, we understand the importance of keeping your heart healthy and functioning at its best. We believe that a healthy heart is the foundation of a healthy life, and our goal is to provide you with all you need to achieve optimal heart health – a happier heart.
Amarillo Heart Clinical Research Institute (AHCRI)
At the Amarillo Heart Clinical Research Institute (AHCRI), we conduct scientific studies of the cardiovascular system, which includes the heart and blood vessels.
Cardiovascular diseases, such as coronary artery disease, heart failure, and stroke, are major causes of morbidity and mortality worldwide. Cardiovascular research aims to improve our understanding of the underlying mechanisms that lead to these diseases, such as inflammation, oxidative stress, abnormal lipid metabolism, and new targets for therapy.
Research in this field includes studies of basic science, clinical trials, epidemiology, and health services research. Basic science studies may focus on molecular and cellular mechanisms, animal models, or genetic studies. Clinical trials aim to test the safety and efficacy of new treatments for cardiovascular diseases while epidemiological studies examine the distribution and determinants of cardiovascular diseases in populations. Health services research investigates the best ways to deliver care to patients with cardiovascular diseases.
Overall, cardiovascular research plays a critical role in advancing our knowledge and improving outcomes for patients with cardiovascular diseases.
Research Team
- Dr. Joaquin Martinez-Arrarás
- Dr. Rajesh Nambiar
- Susan Nguyen, RN
- Heather Ramirez-Bastardo, MA
contact information
- 1660 Point West Parkway, Amarillo TX 79124
- P: -806-463-2153-
- F: -806-463-2197-
- [email protected]
- [email protected]
Current Clinical Trials
Title: Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY)
Phase: 3
Study Type: Placebo-controlled, double-blind, randomized trial
Objective: To evaluate the effect of 10 mg Obicetrapib in participants with underlying HeFH and/or Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled by their lipid-modifying therapies.
Title: Selatogrel Outcome Study in suspected Acute Myocardial Infarction (SOS-AMI)
Phase: 3
Study Type: Multi-center, double-blind, randomized, placebo-controlled, parallel-group study
Objective: To evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction.
Upcoming Clinical Trials
Librexia af
Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation
Phase: 3
Study Type: Randomized, double-blind, double-dummy, parallel-group study
Objective: To evaluate the efficacy and safety of Milvexian, an oral Factor XIa inhibitor, compared to Apixaban in participants with Atrial Fibrillation.
ClinicalTrials.gov Identifier: Not yet available
Librexia acs
Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome
Phase: 3
Study Type: Randomized, double-blind, placebo-controlled, event-driven study
Objective: To demonstrate the efficacy and safety of Milvexian, an oral Factor XIa inhibitor, after a recent Acute Coronary Syndrome.
ClinicalTrials.gov Identifier: Not yet available
